Rapport Therapeutics (NASDAQ:RAPP) Issues Quarterly Earnings Results

Posted by Brian Himes on Aug 5th, 2026

Rapport Therapeutics (NASDAQ:RAPP – Get Free Report) released its earnings results on Wednesday. The company reported ($1.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.96) by ($0.23), FiscalAI reports.

Rapport Therapeutics Price Performance

Rapport Therapeutics stock traded up $0.33 during trading on Wednesday, reaching $42.52. 126,208 shares of the company were exchanged, compared to its average volume of 349,656. Rapport Therapeutics has a 52-week low of $13.62 and a 52-week high of $44.28. The stock’s 50 day simple moving average is $39.46 and its two-hundred day simple moving average is $34.23. The company has a market capitalization of $2.03 billion, a P/E ratio of -16.36 and a beta of 0.97.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the company. William Blair assumed coverage on Rapport Therapeutics in a research report on Tuesday, July 28th. They set an “outperform” rating on the stock. Leerink Partners initiated coverage on Rapport Therapeutics in a research report on Wednesday, June 24th. They issued an “outperform” rating and a $52.00 price objective for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Rapport Therapeutics in a research note on Friday, July 17th. Citigroup restated a “market outperform” rating on shares of Rapport Therapeutics in a report on Tuesday, June 2nd. Finally, Truist Financial assumed coverage on shares of Rapport Therapeutics in a research note on Monday, May 18th. They set a “buy” rating and a $56.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Rapport Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $57.86.

View Our Latest Analysis on RAPP

Insider Activity at Rapport Therapeutics

In other news, CEO Abraham Ceesay sold 2,210 shares of the business’s stock in a transaction dated Monday, July 27th. The stock was sold at an average price of $42.11, for a total transaction of $93,063.10. Following the completion of the transaction, the chief executive officer directly owned 537,607 shares of the company’s stock, valued at approximately $22,638,630.77. The trade was a 0.41% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Rock Ventures V. L.P. Third sold 271,495 shares of the business’s stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $40.12, for a total transaction of $10,892,379.40. Following the transaction, the insider owned 6,437,733 shares of the company’s stock, valued at approximately $258,281,847.96. The trade was a 4.05% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 430,913 shares of company stock valued at $17,308,315 over the last quarter. 12.48% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Rapport Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Rapport Therapeutics by 86.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,887 shares of the company’s stock valued at $99,000 after purchasing an additional 4,582 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC acquired a new stake in Rapport Therapeutics during the 1st quarter worth $2,039,000. Rhumbline Advisers lifted its position in Rapport Therapeutics by 40.1% in the first quarter. Rhumbline Advisers now owns 14,358 shares of the company’s stock valued at $144,000 after acquiring an additional 4,109 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Rapport Therapeutics by 5.5% during the second quarter. Geode Capital Management LLC now owns 333,159 shares of the company’s stock worth $3,789,000 after purchasing an additional 17,496 shares in the last quarter. Finally, Creative Planning purchased a new position in Rapport Therapeutics during the 2nd quarter worth approximately $121,000.

Rapport Therapeutics Company Profile

(Get Free Report)

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.